STOCK TITAN

Conmed Corp - CNMD STOCK NEWS

Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.

Conmed Corporation (CNMD) is a globally recognized medical technology company headquartered in Utica, New York. Specializing in the design, manufacturing, and distribution of surgical and patient monitoring products, Conmed plays a pivotal role in advancing healthcare outcomes. The company’s mission is to improve the quality of healthcare through innovative and high-quality medical solutions that empower healthcare professionals to deliver superior patient care.

Core Business Areas

Conmed operates across several key medical specialties, including:

  • Orthopedics: Providing advanced surgical tools and implants for sports medicine and other orthopedic procedures.
  • General Surgery: Offering devices and instruments designed to enhance surgical precision and efficiency.
  • Gynecology: Delivering specialized products tailored for women’s health and minimally invasive procedures.
  • Gastroenterology and Pulmonology: Supplying innovative solutions for diagnostic and therapeutic interventions in the digestive and respiratory systems.
  • Anesthesiology: Developing patient monitoring systems that ensure safety and reliability during surgical procedures.

Global Reach and Market Presence

With a strong presence in the United States, Europe, the Middle East, Africa, Asia Pacific, and North America, Conmed serves a diverse range of healthcare providers worldwide. Its products are trusted by surgeons and medical professionals across multiple specialties, showcasing its commitment to enhancing patient outcomes on a global scale.

Business Model and Revenue Generation

Conmed generates revenue through the direct sale of its medical devices and equipment to hospitals, surgical centers, and healthcare institutions. By focusing on customer satisfaction and building long-term partnerships, the company ensures a steady demand for its innovative solutions. Its emphasis on research and development enables the continuous introduction of cutting-edge technologies that address evolving medical needs.

Competitive Landscape

Operating within the highly competitive medical technology industry, Conmed faces competition from major players such as Medtronic, Stryker, and Johnson & Johnson. The company differentiates itself through its customer-centric approach, commitment to quality, and targeted focus on specific medical specialties. Its ability to innovate and adapt to changing healthcare trends further strengthens its market position.

Commitment to Excellence

Conmed's dedication to improving healthcare extends beyond its products. The company prioritizes thoughtful leadership, employee development, and community engagement. By fostering a culture of innovation and responsibility, Conmed reinforces its role as a trusted partner in the global medical community.

Conclusion

Conmed Corporation exemplifies the integration of cutting-edge technology and a customer-first philosophy within the medical device industry. Its focus on enhancing clinical outcomes, coupled with a robust global presence, positions the company as a key contributor to the advancement of healthcare worldwide. By continuously innovating and maintaining high standards of quality, Conmed remains a vital player in the ever-evolving medical technology landscape.

Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) reported strong first quarter results for 2023, achieving sales of $295.5 million, a 21.9% increase year over year, with a 25.1% rise in constant currency. Domestic sales grew by 25.4%, while international sales rose 17.8% year over year. However, diluted net earnings per share (GAAP) fell to $0.06, an 87.2% decline compared to Q1 2022. Adjusted diluted net earnings per share decreased by 5.7% to $0.66. The company has raised its full-year revenue guidance to between $1.205 billion and $1.250 billion, up from a previous range of $1.170 billion to $1.220 billion. Additionally, adjusted diluted net earnings per share guidance was increased to a range of $3.30 to $3.50.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.33%
Tags
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) will announce its Q1 2023 financial results on April 26, 2023, after market close. Management will host a conference call at 4:30 p.m. ET to discuss these results. Investors can participate via telephone or listen to a webcast on CONMED's website. The company produces surgical devices for various specialties, including orthopedics and general surgery. Forward-looking statements in the release highlight risks from the ongoing COVID-19 pandemic, which may affect operational performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) announced that its Annual Meeting of Stockholders will take place on May 24, 2023, at 1:30 p.m. ET at its headquarters in Largo, FL, and virtually. Shareholders of record by March 28, 2023 can vote. Further details will be in a definitive proxy statement filed with the Securities and Exchange Commission on April 11, 2023, available on CONMED's website.

CONMED specializes in surgical devices for minimally invasive procedures across various medical fields. The company emphasizes its commitment to addressing risks and uncertainties, notably those arising from the ongoing COVID-19 pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
none
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) has announced that Curt R. Hartman, Chair and CEO, along with Todd W. Garner, CFO, will participate in a virtual fireside chat at the KeyBanc Life Sciences and MedTech Investor Forum. This event is scheduled for 9:00 a.m. ET on March 22, 2023. A live audio webcast will be available on the Company’s website, with a replay following the event. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and gastroenterology. For more information, visit www.conmed.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
conferences
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share. The dividend is payable on April 5, 2023, to shareholders of record as of March 15, 2023. This announcement reflects the company's ongoing commitment to returning value to its shareholders.

CONMED specializes in providing surgical devices and equipment for minimally invasive procedures in various medical specialties, including orthopedics and gastroenterology. Further details can be found on their official website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
dividends
-
Rhea-AI Summary

CONMED reported Q4 2022 sales of $250.9 million, an 8.4% decline year-over-year, with domestic revenue down 3.9% and international revenue down 13.8%. Diluted net earnings per share (GAAP) rose 14.7% to $0.86, while adjusted earnings fell 60.7% to $0.42. For full-year 2022, sales grew 3.4% to $1,045.5 million. However, the company reported a diluted net loss per share of $2.68, contrasting with earnings of $1.94 in 2021. For 2023, CONMED forecasts revenue between $1.170 billion and $1.220 billion, with adjusted EPS expected at $3.20 to $3.45.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) is set to release its fourth quarter 2022 financial results on February 2, 2023, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the outcomes. Participants can pre-register for the call or access a live webcast on CONMED's website. The company specializes in surgical devices for minimally invasive procedures across various medical fields. The press release includes forward-looking statements regarding the impact of the COVID-19 pandemic on the business and operating volumes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share. This dividend will be payable on January 5, 2023, to shareholders of record as of December 16, 2022. CONMED specializes in providing surgical devices and equipment for minimally invasive procedures across various medical specialties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
dividends
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) announced participation in the 34th Annual Piper Sandler Healthcare Conference, with a fireside chat led by Curt R. Hartman and Todd W. Garner on November 30, 2022, at 3:30 p.m. ET. A live audio webcast will be available on the 'Investors' section of their website and will be replayed afterward. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and general surgery. For more details, visit www.conmed.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
conferences
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) has withdrawn its full-year 2022 financial outlook due to unexpected shipping disruptions caused by new warehouse management software implementation. The backlog peaked at $35 million but has now decreased to $28 million. Despite these challenges, daily shipment volumes have returned to normal, and the company anticipates limited impact on fourth-quarter performance. For 2023, CNMD expects revenue between $1.170 billion and $1.230 billion, with adjusted diluted net earnings per share projected between $3.20 and $3.50.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none

FAQ

What is the current stock price of Conmed (CNMD)?

The current stock price of Conmed (CNMD) is $48.59 as of April 18, 2025.

What is the market cap of Conmed (CNMD)?

The market cap of Conmed (CNMD) is approximately 1.6B.

What does Conmed Corporation specialize in?

Conmed specializes in designing, manufacturing, and distributing surgical and patient monitoring products across various medical specialties.

What are the key medical specialties Conmed serves?

Conmed serves orthopedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology.

How does Conmed generate revenue?

Conmed generates revenue through the direct sale of its medical devices and equipment to healthcare providers globally.

What is Conmed's competitive advantage?

Conmed differentiates itself through its customer-centric approach, innovative solutions, and targeted focus on specific medical specialties.

Where is Conmed Corporation headquartered?

Conmed Corporation is headquartered in Utica, New York, USA.

What is Conmed's global presence?

Conmed operates in the USA, Europe, the Middle East, Africa, Asia Pacific, and North America, serving healthcare providers worldwide.

What is Conmed's mission?

Conmed's mission is to improve healthcare quality by designing, producing, and marketing innovative, high-quality medical products.

Who are Conmed's main competitors?

Conmed competes with companies like Medtronic, Stryker, and Johnson & Johnson in the medical technology industry.

What industries does Conmed operate in?

Conmed operates in the medical technology and healthcare industries, focusing on surgical and patient monitoring solutions.

How does Conmed contribute to healthcare innovation?

Conmed invests in research and development to create cutting-edge medical technologies that enhance clinical outcomes and patient care.
Conmed Corp

NYSE:CNMD

CNMD Rankings

CNMD Stock Data

1.60B
30.76M
0.58%
117.9%
7.45%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
LARGO